AAAiza Ahsan

Aiza Ahsan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aiza Ahsan has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Carvedilol for prevention of cardiotoxicity in patients receiving anthracycline-based chemotherapy: a systematic review and meta-analysis

    by Kainat Mehmood, Syeda Masooma Jafri, Bareeha Haider, Shah Jahan, Aiza Ahsan, Ummama Qadeer, Muhammad Saad Khan, Muhammad Mohsin Khan, Kalpana Singh, Abubakr Mahmoud

  • Open Access

    Efficacy and Safety of Lebrikizumab in the Treatment of Atopic Dermatitis: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

    by Asia Batool, Muhammad Sharjeel Abbas, Saifullah Khan, Alisha Ahmad, Aiza Ahsan, Syeda Masooma Jafri, Makhzan Ali Akbar, Nabahat Shafi, Mrunalini Dandamudi, Prachi Gajjar C, et al.

    Background: Atopic dermatitis is a chronic inflammatory skin condition characterized by eczematous lesions and pruritus, which can significantly impair quality of life. Biologics have been introduced for the treatment; however, due to safety concerns, investigations for these systemic drugs continue. Lebrikizumab, a monoclonal antibody inhibiting IL‐13, not only reduces the immunological response but also minimizes the destructive effects of these cytokines on skin barriers. This meta‐analysis was conducted to assess the efficacy and safety profile of lebrikizumab in patients with atopic dermatitis. Methods: A systematic review and meta‐analysis were conducted in accordance with the PRISMA guidelines. From conception until October 2025, literature was searched on PubMed, Embase, the Cochrane Library, and Scopus. Data were pooled from 4 studies comprising 1037 patients. Outcomes assessed include achievement of IGA (0.1) and ≥ 2‐point score from baseline to 16 weeks, EASI‐75 and EASI‐90 at 16 weeks, DLQI 4‐point improvement, DLQI, and reduction in sleep loss score and adverse events. Standardized mean differences (SMDs) or odds ratios (ORs) were calculated with 95% confidence intervals (CIs), and heterogeneity was examined using the I 2 statistic. Results: Lebrikizumab was significantly superior to placebo in achieving IGA (0.1) (OR = 2.88; 95% CI: 1.73 to 4.79; p < 0.001) and EASI‐75 (OR = 2.98; 95% CI: 1.76 to 5.05; p < 0.001) at Week 16. It was also associated with DLQI 4‐point improvement (OR = 3.99; 95% CI: 1.51 to 10.56; p = 0.005), pruritus NRS ≥ 4‐point improvement (OR = 2.80; 95% CI: 1.56 to 5.04; p = 0.006), and DLQI (MD = −2.13; 95% CI: −3.55 to −0.71) from baseline to 16 weeks. Higher rates of treatment‐emergent adverse events (TEAEs) (OD = 1.42; 95% CI: 1.07 to 1.89; p = 0.02) and moderate AEs (OD = 1.53; 95% CI: 1.04 to 2.25; p = 0.03) were associated with lebrikizumab. The risk of serious adverse effects and infections was comparable across the two groups. Conclusion: Lebrikizumab shows significant benefit in improving atopic dermatitis treatment by IGA (0.1), and ≥ 2‐point reduction, higher EASI‐75 response, and reduction in DLQI and pruritus score. However, lebrikizumab is associated with a higher risk of TEAS and moderate AEs.